Analgesics and Anti-inflammatory Drugs Practice Questions

Q: A patient presents with an acute gout attack. Which medication is contraindicated in the acute setting due to the risk of exacerbating the attack?

Allopurinol. ***Allopurinol*** - Initiating or increasing the dose of **allopurinol** during an acute gout attack can precipitate or worsen the attack. - Allopurinol is a **urate-lowering therapy** that mobilizes uric acid from tissues, potentially leading to a transient increase in serum uric acid during initiation. *Colchicine* - **Colchicine** is a first-line treatment for acute gout attacks, especially when started within 24-36 hours of symptom onset. - It works by inhibiting neutrophil migration and activation, reducing the inflammatory response to uric acid crystals. *Indomethacin* - **Indomethacin** is a non-steroidal anti-inflammatory drug (NSAID) commonly used to treat the acute pain and inflammation of a gout attack. - It rapidly reduces inflammation by inhibiting prostaglandin synthesis, providing symptomatic relief. *Prednisone* - **Prednisone**, a corticosteroid, is effective in treating acute gout attacks, particularly when NSAIDs or colchicine are contraindicated or ineffective. - It powerfully suppresses the inflammatory response, quickly resolving the pain and swelling associated with gout flares.

Q: Which of the following best describes the mechanism of action of monoclonal antibodies used in the treatment of rheumatoid arthritis?

Inhibition of TNF-alpha. ***Inhibition of TNF-alpha*** - Many monoclonal antibodies commonly used in rheumatoid arthritis, such as **infliximab** (Remicade) and **adalimumab** (Humira), specifically target and inhibit **TNF-alpha**. - **TNF-alpha** is a key pro-inflammatory cytokine that plays a central role in the **pathogenesis of rheumatoid arthritis**, promoting inflammation and joint destruction. *Inhibition of T-cell activation* - While T-cell activation is important in RA pathogenesis, specific monoclonal antibodies like **abatacept** (Orencia) work by inhibiting T-cell co-stimulation, rather than directly blocking activation in the same way TNF-alpha inhibitors work. - This mechanism is less broadly representative of the primary action of most monoclonal antibodies used in RA compared to TNF-alpha inhibition. *Blockade of IL-1 receptor* - **Anakinra** (Kineret) is a recombinant **IL-1 receptor antagonist** used in RA, but it is not a monoclonal antibody. - Although IL-1 is a pro-inflammatory cytokine, blocking its receptor is not the primary mechanism of action for the majority of monoclonal antibodies in RA therapy. *Stimulation of B-cell apoptosis* - **Rituximab** (Rituxan) is a monoclonal antibody that targets **CD20 on B-cells**, leading to their depletion, which can indeed induce a degree of B-cell apoptosis. - However, the primary effect is B-cell depletion, and while effective, it is not the most widespread or common mechanism of action for the broader class of monoclonal antibodies used in RA compared to TNF-alpha inhibition.

Q: Which immunosuppressant drug inhibits the mammalian target of rapamycin (mTOR) pathway and prevents T-cell proliferation?

Sirolimus. ***Sirolimus*** - **Sirolimus** (also known as rapamycin) is a macrolide lactone that specifically targets the **mTOR** pathway by binding to FKBP-12, forming a complex that inhibits mTOR [3]. - Inhibition of the **mTOR** pathway prevents **T-cell proliferation**, B-cell proliferation, and antibody production, thus acting as a potent immunosuppressant often used in transplant medicine [3], [4]. *Azathioprine* - **Azathioprine** is a purine analog that acts as an antimetabolite, ultimately inhibiting **DNA synthesis** and thus suppressing the proliferation of rapidly dividing cells, including lymphocytes. - It does not directly inhibit the **mTOR** pathway; its mechanism involves interfering with the synthesis of genetic material. *Cyclosporine* - **Cyclosporine** is a calcineurin inhibitor that binds to cyclophilin, preventing the activation of **calcineurin** [1]. - Inhibition of **calcineurin** blocks the dephosphorylation of **NFAT**, thereby preventing its translocation to the nucleus and subsequent transcription of IL-2 and other cytokine genes essential for T-cell activation [1]. *Tacrolimus* - **Tacrolimus** is also a **calcineurin inhibitor**, similar to cyclosporine, but it binds to FKBP-12 instead of cyclophilin [2]. - This binding prevents the activation of **calcineurin**, which in turn inhibits the production of **IL-2** and other cytokines necessary for T-cell proliferation and activation [2].

Q: A patient with an autoimmune disease receives a biological agent that inhibits TNF-alpha. Identify the drug:

Infliximab. ***Infliximab*** - **Infliximab** is a **chimeric monoclonal antibody** that functions as a tumor necrosis factor-alpha (TNF-alpha) inhibitor, directly binding to and neutralizing TNF-alpha. - It is effectively used in treating several autoimmune conditions like **rheumatoid arthritis**, **Crohn's disease**, **psoriatic arthritis**, and **ankylosing spondylitis** by reducing inflammation. *Methotrexate* - **Methotrexate** is a **disease-modifying antirheumatic drug (DMARD)** and an **antimetabolite** that inhibits dihydrofolate reductase. - While used in autoimmune diseases, it primarily acts by **interfering with immune cell proliferation** and inflammation, not by directly inhibiting TNF-alpha. *Mycophenolate mofetil* - **Mycophenolate mofetil** is an **immunosuppressant** that selectively inhibits inosine monophosphate dehydrogenase, crucial for de novo purine synthesis in lymphocytes. - It is mainly used in **organ transplantation** to prevent rejection and in certain autoimmune conditions like lupus nephritis, not as a direct TNF-alpha inhibitor. *Azathioprine* - **Azathioprine** is a **prodrug** that is metabolized to 6-mercaptopurine, which then interferes with DNA synthesis, primarily affecting rapidly dividing cells like lymphocytes. - It is used as an immunosuppressant in **autoimmune diseases** and **transplant rejection**, but it does not directly target TNF-alpha.

Q: A patient presents with gouty arthritis. Which drug inhibits the enzyme xanthine oxidase to lower uric acid levels?

Allopurinol. ***Allopurinol*** - **Allopurinol** is a **xanthine oxidase inhibitor** that blocks the conversion of hypoxanthine and xanthine to uric acid [1, 2]. - It is used for the **long-term management** of hyperuricemia in patients with gout [1, 2]. *Colchicine* - **Colchicine** is an **anti-inflammatory agent** that inhibits neutrophil chemotaxis and activation. - It is primarily used for the **acute treatment** of gout flares and **prophylaxis** against recurrent attacks [2, 3], but it does not lower uric acid levels. *Indomethacin* - **Indomethacin** is a **nonsteroidal anti-inflammatory drug (NSAID)** that inhibits prostaglandin synthesis. - It is commonly used for **acute pain relief and inflammation** during a gout attack [2] but does not affect uric acid production. *Probenecid* - **Probenecid** is a **uricosuric agent** that inhibits the reabsorption of uric acid in the renal tubules. - It increases the **excretion of uric acid** and is used in patients who underexcrete uric acid [2], but it does not inhibit xanthine oxidase.

Q: A patient undergoing organ transplantation is given an immunosuppressant that inhibits the mammalian target of rapamycin (mTOR). Which drug is this?

Sirolimus. ***Sirolimus*** - **Sirolimus** (also known as rapamycin) is an immunosuppressant that works by inhibiting the **mammalian target of rapamycin (mTOR)** [2]. - This inhibition blocks the progression of activated T cells from phase G1 to phase S of the cell cycle, thereby preventing T-cell proliferation and cytokine production [2]. *Cyclosporine* - **Cyclosporine** is a calcineurin inhibitor that blocks the production of **interleukin-2 (IL-2)** by T cells [1]. - It does not directly inhibit mTOR; instead, it prevents the dephosphorylation of **NFAT**, crucial for IL-2 gene transcription. *Mycophenolate mofetil* - **Mycophenolate mofetil** is an inhibitor of **inosine monophosphate dehydrogenase**, an enzyme critical for *de novo* purine synthesis, especially in lymphocytes. - This action leads to the inhibition of B-cell and T-cell proliferation without directly affecting the mTOR pathway. *Azathioprine* - **Azathioprine** is a **purine analog** that is metabolized to 6-mercipotent, which then interferes with DNA synthesis. - Its main effect is to inhibit the proliferation of lymphocytes, thereby suppressing both cell-mediated and humoral immunity via non-mTOR mechanisms.

Q: What is the best antagonist of morphine?

Naloxone. ***Naloxone*** - **Naloxone** is a pure opioid antagonist with a high affinity for **mu-opioid receptors**, making it the most effective antidote for morphine overdose. - It rapidly reverses the effects of opioid agonists like morphine, including **respiratory depression** and sedation. *Pentazocine* - **Pentazocine** is an opioid agonist-antagonist, meaning it can produce both opioid effects and opioid reversal, but it is not a pure antagonist. - It has a risk of precipitating **opioid withdrawal** in opioid-dependent individuals and is not the first-line choice for reversing overdose. *Buprenorphine* - **Buprenorphine** is a partial mu-opioid agonist and kappa-opioid antagonist, also known as an agonist-antagonist. - While it has some antagonistic properties, its partial agonistic activity means it can still produce opioid effects and is not ideal for rapid reversal of full opioid agonists. *Nalorphine* - **Nalorphine** is an older opioid antagonist with mixed agonist-antagonist properties, similar to pentazocine. - It is less potent and has fallen out of favor compared to naloxone for reversing opioid overdose due to its own potential for **respiratory depression** and psychotomimetic effects.

Q: Which immunosuppressant drug inhibits the JAK-STAT signaling pathway to prevent T-cell proliferation in autoimmune conditions?

Tofacitinib. ***Tofacitinib*** - Tofacitinib is a **Janus kinase (JAK) inhibitor** that selectively inhibits JAK1 and JAK3, preventing the phosphorylation and activation of **STAT proteins**. - This inhibition disrupts the **JAK-STAT signaling pathway**, which is crucial for the proliferation and function of T-cells in various autoimmune and inflammatory conditions. *Cyclosporine* - Cyclosporine is a **calcineurin inhibitor** that works by binding to cyclophilin, forming a complex that inhibits calcineurin. - This prevents the dephosphorylation of **NFAT (nuclear factor of activated T-cells)**, thereby blocking the transcription of IL-2 and other cytokine genes, but does not act on the JAK-STAT pathway. *Sirolimus* - Sirolimus (rapamycin) is an **mTOR inhibitor** that binds to FKBP-12, forming a complex that inhibits the mammalian target of rapamycin (mTOR). - This inhibition blocks the response to IL-2 and prevents T-cell proliferation by inhibiting crucial cell cycle progression, distinct from the JAK-STAT pathway. *Azathioprine* - Azathioprine is a **purine analog** that acts as a prodrug for 6-mercaptopurine, which is then converted into active metabolites that are incorporated into DNA. - This interferes with **purine synthesis** and DNA replication, thereby inhibiting the proliferation of lymphocytes, but does not directly target the JAK-STAT pathway.

Q: A 35-year-old male is prescribed morphine for severe pain. What is a common side effect of morphine?

Sedation. ***Sedation*** - **Morphine** is an **opioid analgesic** that acts on **central nervous system** opioid receptors, leading to a depressant effect, which manifests as sedation. - This side effect is due to its action on the **brainstem**, affecting various physiological functions including wakefulness. *Hypertension* - **Morphine** typically causes **hypotension** rather than hypertension due to its **vasodilatory effects**. - It can release **histamine**, which contributes to vasodilation and a drop in blood pressure. *Diarrhea* - **Morphine** is well-known for causing **constipation** by decreasing **gastrointestinal motility** and increasing anal sphincter tone. - It increases **non-propulsive contractions** and reduces **propulsive contractions** in the gut, leading to stool retention. *Polyuria* - **Morphine** can actually cause **oliguria** or **urinary retention** due to increased **antidiuretic hormone (ADH) secretion** and contraction of the **bladder sphincter**. - It affects the **renal system** by altering hormonal regulation and smooth muscle tone, not by increasing urine output.

Question 1

A patient presents with an acute gout attack. Which medication is contraindicated in the acute setting due to the risk of exacerbating the attack?

Accepted Answer

Allopurinol

Answer

Colchicine

Answer

Indomethacin

Answer

Prednisone

Question 2

Which of the following best describes the mechanism of action of monoclonal antibodies used in the treatment of rheumatoid arthritis?

Accepted Answer

Inhibition of TNF-alpha

Answer

Inhibition of T-cell activation

Answer

Blockade of IL-1 receptor

Answer

Stimulation of B-cell apoptosis

Question 3

Which immunosuppressant drug inhibits the mammalian target of rapamycin (mTOR) pathway and prevents T-cell proliferation?

Accepted Answer

Sirolimus

Answer

Azathioprine

Answer

Cyclosporine

Answer

Tacrolimus

Question 4

A patient with an autoimmune disease receives a biological agent that inhibits TNF-alpha. Identify the drug:

Accepted Answer

Infliximab

Answer

Azathioprine

Answer

Mycophenolate mofetil

Answer

Methotrexate

Question 5

A patient presents with gouty arthritis. Which drug inhibits the enzyme xanthine oxidase to lower uric acid levels?

Accepted Answer

Allopurinol

Answer

Colchicine

Answer

Indomethacin

Answer

Probenecid

Question 6

A patient undergoing organ transplantation is given an immunosuppressant that inhibits the mammalian target of rapamycin (mTOR). Which drug is this?

Accepted Answer

Sirolimus

Answer

Cyclosporine

Answer

Mycophenolate mofetil

Answer

Azathioprine

Question 7

What is the best antagonist of morphine?

Accepted Answer

Naloxone

Answer

Buprenorphine

Answer

Pentazocine

Answer

Nalorphine

Question 8

A patient on long-term NSAID therapy develops peptic ulcer disease. What approach should be taken to manage both conditions effectively?

Accepted Answer

Switch to a COX-2 inhibitor and start a proton pump inhibitor

Answer

Continue NSAID and add an H2 receptor antagonist

Answer

Discontinue NSAID and switch to acetaminophen

Answer

Add a high-dose antacid regimen

Question 9

Which immunosuppressant drug inhibits the JAK-STAT signaling pathway to prevent T-cell proliferation in autoimmune conditions?

Accepted Answer

Tofacitinib

Answer

Cyclosporine

Answer

Sirolimus

Answer

Azathioprine

Question 10

A 35-year-old male is prescribed morphine for severe pain. What is a common side effect of morphine?

Accepted Answer

Sedation

Answer

Hypertension

Answer

Diarrhea

Answer

Polyuria

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?